GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) --. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage ...
On April 16, 2024, the United States Patent and Trademark Office issued patent number 11957664 to Adial Pharmaceuticals Inc ...
Hosted on MSN21d
Adial stock rallies 81% on data for alcohol abuse drugAdial Pharmaceuticals (NASDAQ:ADIL) stock rallied 81% in morning trading Wednesday amid the publication of encouraging data for the company's alcohol use disorder drug AD04. The data were featured ...
Adial Pharmaceuticals shares were up 78% at $2.01 after the company provided promising clinical results, strong safety profile and high compliance among patients administered AD04, or low-dose ...
The publication also reported new study results analyzing the liver safety profile of AD04 compared with placebo in alcohol use disorder. Low-dose AD04 did not significantly change biochemical ...
Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year-End 2023 GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW ...
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead ...
GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback